These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33495216)

  • 1. Reply to Béranger et al., "Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children".
    Saito J; Shoji K; Oho Y; Kato H; Matsumoto S; Aoki S; Nakamura H; Ogawa T; Hasegawa M; Yamatani A; Miyairi I
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495216
    [No Abstract]   [Full Text] [Related]  

  • 2. Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children.
    Béranger A; Bouazza N; Oualha M
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495214
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
    Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
    J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
    Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of meropenem during advanced organ support (ADVOS
    König C; Kluge S; Fuhrmann V; Jarczak D
    Int J Artif Organs; 2021 Oct; 44(10):783-786. PubMed ID: 34144656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
    Jamal JA; Udy AA; Lipman J; Roberts JA
    Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
    Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
    Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
    J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Authors response: "Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study".
    Liebchen U; Scharf C
    J Crit Care; 2022 Aug; 70():154060. PubMed ID: 35623109
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter to the editor: "Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study".
    Honore PM; Redant S; Djimafo P; Preseau T; Cismas BV; Kaefer K; Barreto Gutierrez L; Anane S; Gallerani A; Attou R
    J Crit Care; 2022 Aug; 70():154028. PubMed ID: 35561559
    [No Abstract]   [Full Text] [Related]  

  • 16. Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.
    Petersson J; Giske CG; Eliasson E
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.
    Krueger WA; Schroeder TH; Hutchison M; Hoffmann E; Dieterich HJ; Heininger A; Erley C; Wehrle A; Unertl K
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2421-4. PubMed ID: 9736574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
    Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
    Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
    Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
    Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.